[HTML][HTML] Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
Q He, J Liu, X Cai, M He, C Li, H Liang… - … Cancer Research, 2021 - ncbi.nlm.nih.gov
… This is a retrospective study of a prospectively maintained cohort. The aims of this study were
to compare the efficacy among three first-generation EGFR-TKIs as adjuvant treatment and …
to compare the efficacy among three first-generation EGFR-TKIs as adjuvant treatment and …
[HTML][HTML] The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non …
HA Jung, SY Woo, SH Lee, JS Ahn… - … Cancer Research, 2020 - ncbi.nlm.nih.gov
… 17.3 months for gefitinib, 12.4 months for erlotinib, and 23.3 … –0.83) compared with gefitinib
or erlotinib. In the competing … failure compared with gefitinib or erlotinib after adjusting for both …
or erlotinib. In the competing … failure compared with gefitinib or erlotinib after adjusting for both …
Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting
WC Kwok, JCM Ho, TCC Tam, MSM Ip… - Thoracic …, 2022 - Wiley Online Library
… A retrospective cohort study of Chinese patients with metastatic NSCLC harboring EGFR
mutations who received first-line gefitinib, erlotinib or afatinib treatment, followed by osimertinib …
mutations who received first-line gefitinib, erlotinib or afatinib treatment, followed by osimertinib …
Comparing the effectiveness of different EGFR‐TKIs in patients with EGFR mutant non–small‐cell lung cancer: a retrospective cohort study in Taiwan
YY Hsieh, WT Fang, YW Lo, YH Chen… - International journal of …, 2020 - Wiley Online Library
… This retrospective cohort study was conducted using data from real-world settings. Patients
with stage IIIB and IV NSCLC and first received gefitinib, erlotinib, or afatinib between 2011 …
with stage IIIB and IV NSCLC and first received gefitinib, erlotinib, or afatinib between 2011 …
Nationwide real-world cohort study of first-line tyrosine kinase inhibitor treatment in epidermal growth factor receptor-mutated non–small-cell lung cancer
RGP Gijtenbeek, RAM Damhuis, HJM Groen… - Clinical lung cancer, 2020 - Elsevier
… erlotinib, we observed a poorer adjusted survival for gefitinib … , this study is the largest
European real-world cohort of … erlotinib, we observed a poorer adjusted survival for gefitinib …
European real-world cohort of … erlotinib, we observed a poorer adjusted survival for gefitinib …
Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib
CH Lee, MC Shen, MJ Tsai, JS Chang, YB Huang… - Scientific Reports, 2022 - nature.com
… -based cohort study demonstrated that concurrent PPI with gefitinib or erlotinib was
associated with significantly poorer OS and TTNT than the H2RA and non-user. Other studies …
associated with significantly poorer OS and TTNT than the H2RA and non-user. Other studies …
First-or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
ACC Huang, CH Huang, JS Ju… - Therapeutic …, 2021 - journals.sagepub.com
… The slightly higher T790M yield of both the gefitinib/erlotinib and afatinib groups in the
present study might be related to the addition of a liquid biopsy when a tissue biopsy was …
present study might be related to the addition of a liquid biopsy when a tissue biopsy was …
… kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study
WW Ng, CC Lin, CY Cheng, JS Jiang, SJ Kao, DY Yeh - Plos one, 2021 - journals.plos.org
… gefitinib and afatinib groups (p = 0.009). Patients on afatinib also had longer median OS than
erlotinib and gefitinib … a better choice compared to gefitinib or erlotinib for EGFRm+ patients…
erlotinib and gefitinib … a better choice compared to gefitinib or erlotinib for EGFRm+ patients…
Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients
C Wang, K Zhao, S Hu, W Dong, Y Gong, M Li, C Xie - Lung Cancer, 2022 - Elsevier
… The purpose of this study was to investigate the outcomes of gefitinib and erlotinib in patients
with non-small cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (…
with non-small cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (…
Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post‐authorization safety cohort study conducted in Europe and …
V Ehrenstein, K Huang, J Kahlert… - … and Drug Safety, 2021 - Wiley Online Library
… erlotinib or gefitinib, we excluded patients with a previous dispensing of erlotinib or gefitinib;
and … patient entered one of the 4 cohorts: crizotinib cohort; ceritinib cohort; erlotinib cohort, or …
and … patient entered one of the 4 cohorts: crizotinib cohort; ceritinib cohort; erlotinib cohort, or …
相关搜索
- retrospective cohort study
- small cell lung cancer cohort study
- gefitinib erlotinib and icotinib
- gefitinib erlotinib and afatinib
- gefitinib and erlotinib in patients
- gefitinib and erlotinib common egfr mutation
- gefitinib or erlotinib proton pump inhibitors
- nationwide real world cohort study
- gefitinib erlotinib egfr tki
- gefitinib and erlotinib first line setting
- gefitinib and erlotinib survival benefits
- gefitinib erlotinib clinical efficacy
- gefitinib or erlotinib lung cancer patients
- gefitinib and erlotinib pooled analysis
- tyrosine kinase inhibitor treatment cohort study
- epidermal growth factor cohort study